Compounds selected from the group consisting of: trans-6-Acetyl-4S-(3,5-difluorobenzoylamino)-3,4-dihydro-2,2-dimethyl- 2H-1-benzopyran-3R-ol, trans-6-Acetyl-4S-(2,3,4-trifuorobenzoylamino)-3,4-dihydro-2,2-dimethy l-2H-1-benzopyran-3R-ol, trans-6-Acetyl-4S-(5-fluoro-2-methylbenzoylamino)-3,4-dihydro-2,2-dime thyl-2H-1-benzopyran-3R-ol, and trans-7-Acetyl-4-(4-fluorobenzoylamino)-3,4-dihydro-2,2-dimethyl-2H-1- benzopyran-3-ol are useful in the treatment and/or prophylaxis of anxiety, mania, depression, disorders associated with a subarachnoid haemorrhage or neural shock, the effects associated with withdrawal from substances of abuse such as cocaine, nicotine, alcohol and benzodiazepines, disorders treatable or preventable with anti-convulsive agents; such as epilepsy; Parkinson's disease, psychosis, migraine, cerebral ischaemia, Alzheimer's disease, schizophrenia and/or aggression.
Benzopyrans and their use as therapeutic agents